Table 2.

Disease activity indices at baseline and after the initiation of anti-TNF treatment [mean (SD)].

	Visit (no. of patients evaluated)
	Baseline (n=186)	Month 1 (n=186)	Month 3 (n=172)	Month 6 (n=158)	Month 12 (n=146)	Month 24 (n=97)	Month 36 (n=58)	Month 48 (n=39)
Core set criteria
Physicians’ global assessment of disease activity*	7.1 (1.7)	5.1 (2.1)**	4.2 (2.1)	3.6 (2.0)	2.9 (1.8)	2.5 (1.8)	3.0 (2.2)	2.4 (1.6)
Patient/parent global assessment of disease activity*	7.3 (1.9)	4.7 (2.3)**	3.8 (2.2)	3.3 (2.0)	2.7 (2.0)	2.3 (1.8)	2.8 (2.2)	2.0 (1.6)
Number of joints with active arthritis	10.0 (9.9)	6.4 (8.9)**	4.9 (8.6)	3.2 (5.2)	2.5 (4.1)	2.1 (4.0)	2.8 (3.9)	2.6 (3.8)
Number of joints with limited ROM	7.9 (9.0)	5.5 (8.3)**	4.6 (8.1)	3.7 (5.6)	3.1 (4.8)	2.6 (4.0)	3.3 (4.7)	3.2 (4.7)
CHAQ score	1.4 (0.7)	0.9 (0.7)**	0.7 (0.7)	0.6 (0.7)	0.5 (0.6)	0.4 (0.5)	0.5 (0.5)	0.3 (0.4)
ESR (mm/h)	38 (25.5)	16 (15.4)**	13 (12.3)	15 (17.1)	12 (9.4)	12 (12.2)	13 (12.2)	10 (6.6)
CRP (mg/L)	32 (41.0)	11 (25.5)**	8 (19.0)	6 (13.3)	4 (11.3)	6 (19.4)	6 (13.5)	4 (6.9)
Additional criteria
Duration of morning stiffness (min)	84 (71.0)	32 (42.3)**	19 (31.0)	14 (27.0)	9 (20.5)	7 (16.4)	8 (18.8)	9 (30.3)
Physician assessment of treatment efficacy*	2.2 (2.1)	6.3 (2.0)**	7.0 (1.9)	7.5 (1.7)	7.9 (1.8)	8.2 (1.6)	7.8 (1.9)	8.3 (1.5)
Parent assessment of treatment efficacy*	2.3 (2.3)	6.7 (2.0)**	7.4 (1.9)	7.9 (1.8)	8.1 (1.8)	8.5 (1.5)	8.3 (1.6)	8.7 (1.3)
Patient assessment of treatment efficacy*	2.3 (2.3)	6.8 (2.0)**	7.5 (1.9)	8.0 (1.8)	8.2 (1.8)	8.6 (1.5)	8.1 (2.0)	8.4 (1.9)

^*(VAS, 0–10 cm);

^**p<0.0001 (paired Wilcoxon test) for the difference between baseline and all subsequent visits;

ROM – range of motion; CHAQ – Children Health Assessment Questionnaire; ESR – erythrocyte sedimentation rate; CRP – C-reactive protein.